TGF-β: the master regulator of fibrosis

Area of Science:

• Nephrology
• Molecular Biology
• Fibrosis Research

Background:

• Transforming growth factor-β (TGF-β) is a key driver of fibrosis in chronic kidney disease (CKD).
• TGF-β1 signaling, via canonical (Smad) and non-canonical pathways, promotes renal fibrosis by activating myofibroblasts and increasing extracellular matrix (ECM) production.
• The role of Smad proteins in fibrosis is complex, involving both pro- and anti-fibrotic actions and interactions with other signaling pathways.

Purpose of the Study:

• To review the mechanisms by which TGF-β1 induces renal fibrosis in CKD.
• To highlight recent findings on regulatory mechanisms of TGF-β1/Smad signaling.
• To identify potential alternative therapeutic targets for halting fibrosis in CKD.

Main Methods:

• Literature review of studies on TGF-β1 signaling and renal fibrosis.
• Analysis of canonical (Smad) and non-canonical signaling pathways.
• Investigation of novel regulatory mechanisms including noncoding RNAs and epigenetic modifications.

Main Results:

• TGF-β1 overexpression induces renal fibrosis, while inhibition limits it in disease models.
• TGF-β1 activates myofibroblasts and ECM production/inhibition of degradation.
• Recent research identified noncoding RNAs and epigenetic modifications as regulators of TGF-β1/Smad signaling in fibrosis.

Conclusions:

• Direct TGF-β1 targeting is unlikely to be a viable antifibrotic therapy due to its essential functions.
• Understanding the intricate pathways of TGF-β1-mediated fibrosis offers opportunities for novel therapeutic strategies.
• Targeting specific downstream pathways or regulatory mechanisms presents a promising approach for treating renal fibrosis in CKD.